BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Soendergaard C, Seidelin JB, Steenholdt C, Nielsen OH. Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterol 2018;5:e000208. [PMID: 29915667 DOI: 10.1136/bmjgast-2018-000208] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Lindholm CR, Siegel CA. Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials? Curr Pharm Des 2019;25:64-8. [PMID: 30864506 DOI: 10.2174/1381612825666190312113935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
3 Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]
4 Chen Y, Li H, Feng Q, Shen J. Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients. Front Pharmacol 2021;12:654985. [PMID: 33986682 DOI: 10.3389/fphar.2021.654985] [Reference Citation Analysis]
5 Yuan CW, Sun XL, Qiao LC, Xu HX, Zhu P, Chen HJ, Yang BL. Non-SMC condensin I complex subunit D2 and non-SMC condensin II complex subunit D3 induces inflammation via the IKK/NF-κB pathway in ulcerative colitis. World J Gastroenterol 2019; 25(47): 6813-6822 [PMID: 31885422 DOI: 10.3748/wjg.v25.i47.6813] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
6 Hashash JG, Mourad FH. Positioning biologics in the management of moderate to severe Crohn's disease. Curr Opin Gastroenterol 2021;37:351-6. [PMID: 33731644 DOI: 10.1097/MOG.0000000000000735] [Reference Citation Analysis]
7 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis 2019;4:79-96. [PMID: 31559260 DOI: 10.1159/000500721] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
9 Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med 2020;9:E1323. [PMID: 32370274 DOI: 10.3390/jcm9051323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Bilsborough J, Fiorino MF, Henkle BW. Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis. Expert Opin Drug Discov 2021;16:567-77. [PMID: 33245673 DOI: 10.1080/17460441.2021.1851185] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
12 Bertani L, Baglietto L, Antonioli L, Fornai M, Tapete G, Albano E, Ceccarelli L, Mumolo MG, Pellegrini C, Lucenteforte E, de Bortoli N, Bellini M, Marchi S, Blandizzi C, Costa F. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol 2020;86:1296-305. [PMID: 32027388 DOI: 10.1111/bcp.14235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
13 Mahajna H, Ben-Horin S. Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseases. Curr Opin Pharmacol 2020;55:132-40. [PMID: 33249396 DOI: 10.1016/j.coph.2020.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Felice C, Pugliese D, Guidi L. TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine. EBioMedicine 2019;41:40-1. [PMID: 30808577 DOI: 10.1016/j.ebiom.2019.02.045] [Reference Citation Analysis]
15 Wang C, Baer HM, Gaya DR, Nibbs RJB, Milling S. Can molecular stratification improve the treatment of inflammatory bowel disease? Pharmacol Res 2019;148:104442. [PMID: 31491469 DOI: 10.1016/j.phrs.2019.104442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Zhao M, Bendtsen F, Petersen AM, Larsen L, Dige A, Hvas C, Seidelin JB, Burisch J. Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy-the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study. BMJ Open 2020;10:e035756. [PMID: 32102828 DOI: 10.1136/bmjopen-2019-035756] [Reference Citation Analysis]
17 Shi Y, He W, Zhong M, Yu M. MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases. Genomics 2021;113:1988-98. [PMID: 33872704 DOI: 10.1016/j.ygeno.2021.04.011] [Reference Citation Analysis]
18 Bertani L, Antonioli L, Fornai M, Tapete G, Baiano Svizzero G, Marchi S, Blandizzi C, Costa F. Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. Minerva Gastroenterol Dietol 2019;65:298-308. [PMID: 31646851 DOI: 10.23736/S1121-421X.19.02621-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
19 Verstockt B, Verstockt S, Veny M, Dehairs J, Arnauts K, Van Assche G, De Hertogh G, Vermeire S, Salas A, Ferrante M. Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020;18:1142-1151.e10. [PMID: 31446181 DOI: 10.1016/j.cgh.2019.08.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]